The results for OS and PFI revealed that low methylation levels of MCMBP were associated with poor prognosis (Figures 5C, D), suggesting that the methylation status of MCMBP may serve as a potential prognostic biomarker for PAAD. This evidence concerns the gene MCMBP and pancreatic adenocarcinoma.